No Data
No Data
Transmedics Group Insider Sold Shares Worth $693,780, According to a Recent SEC Filing
Medical Technology Firms Face Price Target Revisions From Morgan Stanley
Morgan Stanley Adjusts Price Target on TransMedics Group to $103 From $80, Maintains Equalweight Rating
TransMedics Group Stock Is Up 81% in 2025. Can It Climb Even Higher?
We Like These Underlying Return On Capital Trends At TransMedics Group (NASDAQ:TMDX)
TransMedics Group, Inc. (TMDX): A Bull Case Theory